Education
About Us
Working with TipRanks
Follow Us
Lepu Biopharma Co. Ltd. Class H (HK:2157)
:2157
RESEARCH TOOLSreports
2157 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$2.16 - HK$6.52
Previous CloseN/A
Volume4.02M
Average Volume (3M)24.26M
Market Cap
HK$9.22B
Enterprise ValueHK$8.19B
Total Cash (Recent Filing)HK$464.91M
Total Debt (Recent Filing)¥850.16M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Aug 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding1,750,171,500
10 Day Avg. Volume22,981,360
30 Day Avg. Volume24,256,379
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)11.38
Price to Sales (P/S)0.00
P/FCF Ratio-60.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Lepu Biopharma Co. Ltd. Class H News
PremiumCompany Announcements
Lepu Biopharma Completes HK$462.94 Million H Share Placement
PremiumCompany Announcements
Lepu Biopharma Announces HK$462.94 Million H Share Placement
PremiumCompany Announcements
Lepu Biopharma Enhances Governance with New Nomination Committee
PremiumCompany Announcements
Lepu Biopharma’s AGM Approves Key Resolutions for 2024
PremiumCompany Announcements
Lepu Biopharma Announces Changes to Nomination Committee
PremiumCompany Announcements
Lepu Biopharma Secures Hong Kong Stock Exchange Listing Approval
PremiumCompany Announcements
Lepu Biopharma Announces 2024 AGM with Key Resolutions
PremiumCompany Announcements
Lepu Biopharma Announces Board Changes with New Director AppointmentOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
<0.01%
Mutual Funds
― Other Institutional Investors
99.21% Public Companies and
Individual Investors
2157 FAQ
What was Lepu Biopharma Co. Ltd. Class H’s price range in the past 12 months?
Lepu Biopharma Co. Ltd. Class H lowest stock price was HK$2.16 and its highest was HK$6.52 in the past 12 months.
What is Lepu Biopharma Co. Ltd. Class H’s market cap?
Lepu Biopharma Co. Ltd. Class H’s market cap is HK$9.22B.
When is Lepu Biopharma Co. Ltd. Class H’s upcoming earnings report date?
Lepu Biopharma Co. Ltd. Class H’s upcoming earnings report date is Aug 21, 2025 which is in 33 days.
How were Lepu Biopharma Co. Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is Lepu Biopharma Co. Ltd. Class H overvalued?
According to Wall Street analysts Lepu Biopharma Co. Ltd. Class H’s price is currently Overvalued.
Does Lepu Biopharma Co. Ltd. Class H pay dividends?
Lepu Biopharma Co. Ltd. Class H does not currently pay dividends.
What is Lepu Biopharma Co. Ltd. Class H’s EPS estimate?
Lepu Biopharma Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lepu Biopharma Co. Ltd. Class H have?
Lepu Biopharma Co. Ltd. Class H has 1,750,171,500 shares outstanding.
What happened to Lepu Biopharma Co. Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Lepu Biopharma Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2157
Lepu Biopharma Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
117.40%
12-Months-Change
Fundamentals
Return on Equity
-51.40%
Trailing 12-Months
Asset Growth
-7.63%
Trailing 12-Months
Company Description
Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co. Ltd. Class H (2157) is a Chinese biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative pharmaceuticals. The company's primary areas of expertise include oncology, cardiovascular, and other critical therapeutic sectors. Lepu Biopharma is committed to delivering high-quality, cutting-edge healthcare solutions through its robust product pipeline and advanced technological capabilities.
Technical Analysis
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
CARsgen Therapeutics Holdings Ltd.
―
Keymed Biosciences, Inc.
―
Ascletis Pharma, Inc.
―
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
―